AZD-4818

• CAT Number: I003661
• CAS Number: 1003566-93-5
• Molecular Formula: C27H32Cl2N2O7
• Molecular Weight: 567.46
• Purity: ≥95%
• Synonyms: 2-[2-chloro-5-[(2S)-3-(5-chlorospiro[3H-1-benzofuran-2,4′-piperidine]-1′-yl)-2-hydroxypropoxy]-4-(methylcarbamoyl)phenoxy]-2-methylpropanoic acid
• IUPAC Name: 2-[2-chloro-5-[(2S)-3-(5-chlorospiro[3H-1-benzofuran-2,4'-piperidine]-1'-yl)-2-hydroxypropoxy]-4-(methylcarbamoyl)phenoxy]-2-methylpropanoic acid
• InChI: InChI=1S/C27H32Cl2N2O7/c1-26(2,25(34)35)37-23-12-22(19(11-20(23)29)24(33)30-3)36-15-18(32)14-31-8-6-27(7-9-31)13-16-10-17(28)4-5-21(16)38-27/h4-5,10-12,18,32H,6-9,13-15H2,1-3H3,(H,30,33)(H,34,35)/t18-/m0/s1
• InChIKey: HVTUHSABWJPWNK-SFHVURJKSA-N
• SMILES: CC(C)(C(=O)O)OC1=C(C=C(C(=C1)OC[C@H](CN2CCC3(CC2)CC4=C(O3)C=CC(=C4)Cl)O)C(=O)NC)Cl

AZD-4818（Cat No.:I003661）is an investigational small-molecule inhibitor targeting Toll-like receptor 7 (TLR7), developed by AstraZeneca for the treatment of autoimmune and inflammatory diseases. TLR7 plays a key role in innate immune activation, particularly in the production of type I interferons and pro-inflammatory cytokines. By selectively inhibiting TLR7 signaling, AZD-4818 aims to modulate aberrant immune responses implicated in conditions such as systemic lupus erythematosus (SLE). Preclinical studies have shown its potential to reduce inflammation without broadly suppressing immunity. AZD-4818 is currently being evaluated for safety, tolerability, and pharmacokinetics in clinical trials.